Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma

• Histologically proven squamous cell carcinoma of the esophagus(include cardiac cancer)
• Newly diagnosed patients should be unable or unwilling to surgery
• Recurrence after surgery must have no adjuvant chemotherapy or radiotherapy are allowed
• Patients are required to have dimensionally measurable disease,with an objective measurable focus:preferably the use of spiral computed tomography(CT)and measurements of maximum diameter≥1cm.
• Cooperative Oncology Group performance status 0-2 or KPS score ≥60,survival time ≥3 months
• Neutrophils(ANC)≥1.5×109/L; blood platelets counts(BPC)≥80×109/L
• Hemoglobin(Hgb)≥90g/L ,serum total bilirubin ≤1.0 times the upper normal limit(ULN): alanine aminotransferase and glutamic-oxalacetic transaminase (ALT and AST)≤2.5 ULN
• Serum creatinine (Cr)≤1.5ULN

Exclusion Criteria:

• pregnant or nursing women;
• Female patients at child-bearing age, without taking effective contraceptive methods;
• patients who have pathologic confirmation of other types of tumors (eg, leiomyosarcoma, malignant lymphoma) rather than esophageal cancer;
• patients with tumors other than esophageal cancer ,except cervical carcinoma in situ and skin basal cancer or squamous cell carcinoma received adequate treatment;
• patients with cerebral or meningeal metastasis, intestinal obstruction, or symptomatic pathologic changes of peripheral nerve,NCIC-CTG standard >grade 2
• patients with serious complications such as: serious heart disease remained unstable after treatment, or myocardial infarction, congestive heart failure, unstable angina, frank pericardial effusion or unstable arrhythmias in 6 months before being enrolled into the group; confirmed neuropathy or psychosis, including dementia or epilepsia; uncontrolled infection;active disseminated intravascular coagulation;uncontrolled diabetes, fasting serum glucose> 7.8mmol / L